Peptides Of 3 To 100 Amino Acid Residues Patents (Class 530/300)
  • Patent number: 9006401
    Abstract: Embodiments of the present invention provide processes for preparing thymus extracts and plant or fungal extracts, and more particularly provide compositions (Thyex-1-6A and -6B) produced in accordance with said processes, and methods for treatment of various conditions comprising administration of said compositions including but not limited to impaired physical vigor or aptitude, and aging and/or age-related conditions (arthritis, mobility deficits, loss of appetite, etc.). Additional aspects provide methods for building muscle mass, for reducing exercise recovery period, or for sustaining exercise intensity. Particular aspects relate to preparation of Houttuynia cordata extracts and the use of those extracts as an anti-emetic and/or anti-nausea treatment for a subject in need thereof.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: April 14, 2015
    Assignee: CMI Research Management, LLC
    Inventor: Richard N. Ushijima
  • Patent number: 9005627
    Abstract: Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of ragweed pollen Amb a 1. Such peptides while providing all potential T cell epitopes are devoid of the three-dimensional structure of the original allergen, therefore reducing their ability to bind IgE.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: April 14, 2015
    Assignee: Anergis S.A.
    Inventors: Christophe Reymond, Francois Spertini
  • Patent number: 9006392
    Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: April 14, 2015
    Assignee: Novacta Biosystems Limited
    Inventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
  • Patent number: 9005908
    Abstract: The present invention relates to Mycobacterial infections and provides a method of diagnosing infections of Mycobacterium avium subsp. paratuberculosis (Map), the causative agent of Johne's disease. In addition, the invention also provides as kits for use in the diagnosis of Map infections and vaccines/immunogenic compositions.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: April 14, 2015
    Assignee: Moredun Research Institute
    Inventors: Karen Stevenson, Valerie Margaret Hughes
  • Publication number: 20150099791
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of UTRN. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of UTRN. Methods for modulating expression of UTRN using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of UTRN.
    Type: Application
    Filed: May 16, 2013
    Publication date: April 9, 2015
    Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachussetts General Hospital
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Patent number: 8999651
    Abstract: The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence. This invention provides methods and kits for screening for HNA-3a and HNA-3b specific antibodies, HNA-3a and HNA-3b polypeptides and HNA-3a and HNA-3b nucleic acids in a sample of a biological tissue intended for transplantation.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: April 7, 2015
    Assignees: Ernst-Moritz-Arndt-Universität Greifswald, DRK Blutspendedienst West GmbH
    Inventors: Andreas Greinacher, Jan Wesche, Juergen Bux, Angelika Reil
  • Patent number: 8999690
    Abstract: Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3?-position, their bioconjugates and their uses are described. 1,3?-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1?-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: April 7, 2015
    Assignee: AnaSpec Incorporated
    Inventors: Zhenjun Diwu, Jianheng Zhang, Yi Tang, Xiang Guobing
  • Patent number: 8999346
    Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumour-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the treatment of a tumour or in the treatment or prevention of a tumour relapse, and in the manufacture of medicaments therefore.
    Type: Grant
    Filed: February 16, 2009
    Date of Patent: April 7, 2015
    Assignees: Life Sciences Research Partners VZW, Katholieke Universiteit Leuven
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 8999896
    Abstract: Screening assays that allow for the identification of agents that modulate the activity of N-terminal acetylation of a polypeptide and the Doa10 branch of the N-end rule pathway are provided. Also provided are methods of using an agent that modulates the activity of N-terminal acetylation of a polypeptide and the Doa10 branch of the N-end rule pathway to increase or decrease protein degradation in a cell, and to modulate physiologic and pathologic associated with N-terminal acetylation of a polypeptide and the Doa10 branch of the N-end rule pathway.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: April 7, 2015
    Assignee: California Institute of Technology
    Inventors: Cheol-Sang Hwang, Anna Shemorry, Alexander Varshavsky
  • Patent number: 8999919
    Abstract: The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: April 7, 2015
    Assignee: Trustees of Dartmouth College
    Inventors: Dean R. Madden, Patrick R. Cushing, Prisca Boisguearin, Rudolph Volkmer, Lars Vouilleme
  • Publication number: 20150093400
    Abstract: The present invention provides novel short peptides that are highly effective in inducing involution in a mammary gland of a lactating mammal and cessation of milk production by the gland. The invention further provides pharmaceutical composition comprising the peptides and methods of use thereof including for treating microbial infection in a mammary gland.
    Type: Application
    Filed: March 8, 2013
    Publication date: April 2, 2015
    Inventors: Jose Mario Iscovich, Javier Iscovich
  • Patent number: 8993715
    Abstract: It is an object of the present invention to obtain a labeled protein, and specifically, to separate a labeled protein and the same unlabeled protein. There is provided a labeled protein including: a protein to be labeled having a target protein, at least one or more affinity interaction domains for binding to an affinity support, and at least one or more labeling sites; and a labeling reagent binding to at least one of the labeling sites; wherein the affinity of the labeled protein for the affinity support is difference from that of the protein to be labeled for the affinity support.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: March 31, 2015
    Assignee: Canon Kabushiki Kaisha
    Inventors: Fumio Yamauchi, Satoshi Ogawa, Kengo Kanazaki
  • Patent number: 8992928
    Abstract: The present invention relates, in part, to agents for binding and/or inactivating native ghrelin. These agents include those that specifically bind and/or cleave octanoylated native ghrelin. Such agents include antibodies and enzymes. The agents also include those that can be used to generate antibodies that specifically bind and/or cleave octanoylated native ghrelin. Compositions that include the agents are also provided. Further provided are methods of producing and using the agents and compositions thereof. For instance, the agents and compositions can be used to reduce or eliminate the hunger response activity of octanoylated native ghrelin. Therefore, the agents, compositions and methods provided can be used to suppress appetite and/or treat obesity. In addition, the agents, compositions and methods can be used to treat any disease associated with or caused by ghrelin (e.g., Prader-Willi Syndrome).
    Type: Grant
    Filed: February 11, 2006
    Date of Patent: March 31, 2015
    Inventor: Victor Raso
  • Patent number: 8993714
    Abstract: A streptavidin macromolecular adaptor (SAMA) protein may be used for the controlled assembly of nanostructure building blocks and struts including streptavidin:SAMA complexes.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: March 31, 2015
    Assignee: Imiplex LLC
    Inventors: Francis Raymond Salemme, Patricia C. Weber
  • Patent number: 8993718
    Abstract: The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for identifying therapeutic compounds to treat glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction. The invention is also useful for identifying therapeutic compounds to treat de-glycosylation-associated disorders such as ischemic damage and traumatic injury. The invention also relates in part to assays that are useful for identifying and testing candidate compounds for modulating glycosylation of proteins and also relates in part to compounds to treat glycosylation-associated diseases and disorders.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: March 31, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Benjamin J. Gross, Suzanne Walker Kahne, Jonathan G. Swoboda
  • Patent number: 8993717
    Abstract: Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: March 31, 2015
    Assignee: Imperial Innovations Limited
    Inventors: Guido Franzoso, Albert Andrzej Jaxa-Chamiec, Caroline Minli Rachel Low, Simona Maria Monti, Menotti Ruvo, Laura Tornatore, Catherine Jane Tralau-Stewart
  • Patent number: 8992934
    Abstract: The present specification discloses an immunogenic composition comprising polypeptide, wherein each of the polypeptides has no more than 100 amino acids, which polypeptides comprises one or more sequences having at least 60% homology with any of SEQ ID 1-4, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-4 that has the same length as the epitope, wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (MHC) allele, and wherein the polypeptide is not a complete HIV virus protein.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: March 31, 2015
    Assignee: PepTcell Limited
    Inventors: Gregory Alan Stoloff, Wilson Romero Caparros-Wanderlay
  • Patent number: 8992906
    Abstract: Embodiments herein relate to compositions and methods for engraftment of and increasing survival of muscle cells in a subject in need thereof. In certain embodiments, compositions including myofibers and/or satellite stem cells may be administered to a subject. Other embodiments relate to compositions and methods for introducing one or more compounds to a subject using cell compositions disclosed herein. Still other embodiments relate to uses of these compositions in kits for portable applications and methods.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: March 31, 2015
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Bradley Bruce Olwin, John K. Hall, Kathleen Kelly Tanaka
  • Patent number: 8993250
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: March 31, 2015
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura
  • Patent number: 8993736
    Abstract: The present disclosure provides a photoreactive synthetic regulator of protein function. The present disclosure further provides a light-regulated polypeptide that includes a subject synthetic regulator. Also provided are cells and membranes comprising a subject light-regulated polypeptide. The present disclosure further provides methods of modulating protein function, involving use of light.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: March 31, 2015
    Assignee: The Regents of the University of California
    Inventors: Dirk Trauner, Ehud Y. Isacoff, Richard H. Kramer, Matthew R. Banghart, Doris L. Fortin, Alexandre Mourot
  • Patent number: 8993741
    Abstract: The present invention includes an isolated nucleic acid comprising a nucleic acid sequence encoding a SMN?7 degron and the encoded polypeptide. The invention also includes inhibitors of SMN?7 degron. The invention also includes compositions and methods for mitigating SMN deficiency by targeting inhibition of factors that mediate SMN?7-degron dependent degradation of SMN?7.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: March 31, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Sungchan Cho
  • Patent number: 8993716
    Abstract: Peptides of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-Yp—Zq—R2 (I) its stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of the skin, mucous membranes and/or hair and the treatment and/or care of those conditions, disorders and/or diseases which are improved or prevented by Hsp stimulation.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: March 31, 2015
    Assignees: Lipotec, S.A., BCN Peptides, S.A.
    Inventors: Cristina Carreño Serraïma, Wim Van Den Nest, Ana Sempere Bonete, Antonio Ferrer Montiel, Nuria Almiñana Domenech, Juan Cebrián Puche
  • Publication number: 20150087810
    Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: September 25, 2014
    Publication date: March 26, 2015
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel R. Hostetter, Olga Vasiljeva, Jeanne Grace Flandez
  • Patent number: 8987377
    Abstract: The present invention provides poly(amide) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: March 24, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Stephanie E. Barrett, Marina Busuek, Steven L. Colletti, Robert M. Garbaccio, Erin N. Guidry, Robert A. Kowtoniuk, Jing Liao, Craig A. Parish, Rubina G. Parmar, Tao Pei, Kevin M. Schlosser, David M. Tellers, Sandra C. Tobias, Quang T. Truong, Jacob H. Waldman, Weimin Wang, J. Michael Williams
  • Patent number: 8987412
    Abstract: The present invention relates to peptides having one or more stable, internally-constrained HBS ?-helices, where the peptide is capable of interacting with Ras and related proteins.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: March 24, 2015
    Assignee: New York University
    Inventors: Paramjit Arora, Dafna Bar-Sagi, Anupam Patgiri, Kamlesh Yadav
  • Patent number: 8987203
    Abstract: The present invention relates to methods for selecting a candidate therapeutic agent for controlling mineralization of an extracellular matrix in a tissue of a subject. The invention further relates to a cell culture mineralization model comprising a culture of an extracellular matrix producing cell under conditions that support extracellular matrix formation and matrix maturation, a test compound, and means and methods for determining in expression levels of genes encoding matrix proteins.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: March 24, 2015
    Assignee: Arcarios B.V.
    Inventors: Johannes Petrus Thomas Maria Van Leeuwen, Hermanus Johannes Marco Eijken
  • Patent number: 8986655
    Abstract: PSMA ligands, compositions, and methods therefore are disclosed where the ligand is a peptide having the sequence X1X2CVEVX3QNSCX4X5 where X1-X5 are independently a natural or non-natural amino acid or a peptide having the sequence CALCEFLG [SEQ ID NO: 1]. Especially preferred aspects include diagnostic reagents for detection and/or quantification of PSMA in a sample, therapeutic reagents, and diagnostic imaging reagents.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: March 24, 2015
    Assignee: The Regents of the University of California
    Inventors: Gregory A. Weiss, Jessica Arter, Juan E. Diaz
  • Patent number: 8986703
    Abstract: Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells capable of recognizing at least one epitope from an arthropod saliva protein fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDA or less, and wherein the polypeptides are selected independently from: the polypeptide sequences of SEQ ID 1-44 or sub-sequences from these sequences, the sub-sequences having 7 amino acids or more; or from polypeptide sequences having 85% homology or more with one or more of the above sequences and contained in one or more of the following databases: GenBank, Protein Data Bank (PDB), SwissProt, Protein Information Resource (PIR), Protein Research Foundation (PRF), or CDS translations of these.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: March 24, 2015
    Assignee: PepTcell, Ltd.
    Inventors: Gregory Alan Stoloff, Wilson Romero Caparros-Wanderley
  • Patent number: 8987202
    Abstract: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to the human Factor VII or human Factor VIIa sequence shown in SEQ ID NO:1, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: March 24, 2015
    Assignee: Bayer Healthcare LLC
    Inventors: Jesper Mortensen Haaning, Kim Vilbour Andersen, Claus Bornaes
  • Publication number: 20150080296
    Abstract: Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a protein digestibility corrected amino acid score (PDCAAS) that exceeds a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Inventors: Nathaniel W. Silver, Geoffrey von Maltzahn, Michael J. Hamill, David Arthur Berry
  • Patent number: 8980578
    Abstract: The present invention provides fungal xylanase and/or beta-xylosidase enzymes suitable for use in saccharification reactions. The present application further provides genetically modified fungal organisms that produce xylanase and/or beta-xylosidases, as well as enzyme mixtures exhibiting enhanced hydrolysis of cellulosic material to fermentable sugars, enzyme mixtures produced by the genetically modified fungal organisms, and methods for producing fermentable sugars from cellulose using such enzyme mixtures.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: March 17, 2015
    Assignee: Codexis, Inc.
    Inventors: Ryan Fong, Xiyun Zhang, Chris Noriega, Nicholas Agard, Anupam Gohel, Derek Smith
  • Patent number: 8981044
    Abstract: A lipid membrane structure for delivering a substance into a nucleus of a cell, wherein lipid membrane is modified with (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and/or (b) a polypeptide consisting of an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 1, but including deletion and/or substitution and/or insertion of one or several amino acid residues, and having an activity of promoting migration of the lipid membrane structure into a nucleus of a cell, which can efficiently deliver a nucleic acid into a nucleus of an immunocyte such as dendritic cell.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: March 17, 2015
    Assignee: National University Corporation Hokkaido University
    Inventors: Hideyoshi Harashima, Hidetaka Akita, Mohammad Shaheen Sharif, Takashi Nakamura, Soichiro Ishii, Shiroh Futaki
  • Patent number: 8980274
    Abstract: The invention provides Ehrlichia canis antigens that can be used to detect E. canis infected animals regardless of whether the animals have been vaccinated for E. canis. The invention also provides compositions and methods for determining the presence of E. canis antigens and antibodies.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: March 17, 2015
    Assignee: IDEXX Laboratories, Inc.
    Inventors: Eugene Regis Krah, III, Melissa Beall, Thomas Patrick O'Connor, Jr., Ramaswamy Chandrashekar
  • Patent number: 8981056
    Abstract: The invention disclosed herein relates to methods and materials for producing simvastatin and related compounds such as huvastatin. In particular, the disclosure teaches that variants of the LovD acyltransferase polypeptide can be engineered to exhibit properties that facilitate their use in the production of simvastatin and/or huvastatin. The materials and processes disclosed herein are designed so that fermentation facilities currently producing lovastatin can be converted to producing simvastatin and related compounds with minimal modifications.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: March 17, 2015
    Assignee: The Regents of the University of California
    Inventors: Yi Tang, Xue Gao, Xinkai Xie
  • Patent number: 8981046
    Abstract: The present invention provides synthetic cell platforms. The synthetic cell platforms can be used for culturing cells in vitro. The synthetic cell platforms can also be implanted together with bound cells into an individual. The present invention provides methods of using the platforms to provide cells or progeny of such cells for use in various applications, including clinical applications; and methods of use of the platforms to introduce cells into an individual.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: March 17, 2015
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Kevin Edward Healy, Lauren Little, Patrick Sean Daugherty
  • Patent number: 8980842
    Abstract: The present invention is directed to an active agent with contraceptive properties which corresponds to a peptide fragment of the Latrodectus mirabilisi's venom. The peptide generally includes the amino acid sequence of SEQ ID NO 2 or sequences that are at least 85% similar, obtained by chemical synthesis or through recombinant DNA technologies. Furthermore, a pharmaceutical contraceptive composition comprising the peptide fragment and one or more pharmaceutically acceptable vehicles is also described. The peptide fragment and pharmaceutical compositions are useful as a contraceptive and spermicide agent.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: March 17, 2015
    Assignees: Universidad de la Frontera, Universidad de Chile, Universidad Federal de Sao Paulo, Laboratorios Andromaco S.A.
    Inventors: Fernando Romero Mejia, Raúl Sanchez Gutierrez, Eduardo Bustos Obregón, Antonio De Miranda, Andrés Rudolphy Fontaine
  • Patent number: 8981049
    Abstract: Improved methods of native chemical ligation are provided. The methods involve reacting a thioacid (e.g. a peptide thioacid) with an aziridinyl compound (e.g. an aziridinyl peptide) under mild conditions without the use of protecting groups, and without requiring that a cysteine residue be present in the ligation product. Initial coupling of the thioacid and the aziridinyl compound yields a ligation product which contains an aziridinyl ring. Subsequent opening of the aziridinyl ring (e.g. via a nucleophilic attack) produces a linearized and modified ligation product.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: March 17, 2015
    Assignee: Washington State University
    Inventor: Philip Garner
  • Patent number: 8981045
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: March 17, 2015
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
  • Publication number: 20150073123
    Abstract: Synthetic peptides which have non-narcotic type of analgesic action which may be used in medicine and pharmacology as anesthetic anodynes according to the general formula 1 [SEQ ID NO:1] H-XDL-XDL1-XDL2-L-Lys-L-Leu-XDL3-L-Thr-R2.
    Type: Application
    Filed: December 7, 2012
    Publication date: March 12, 2015
    Inventors: Gennady Petrovich VLASOV, Oleg Arkadyevich KOTIN, Arkadiy Mihajlovich KOTIN
  • Patent number: 8974774
    Abstract: Compositions and methods are provided that are useful for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGF. The compositions and methods are particularly useful for topical delivery of antifungal agents and antigenic agents suitable for immunization. Alternately, the compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: March 10, 2015
    Assignee: Revance Therapeutics, Inc.
    Inventors: Michael D. Dake, Jacob M. Waugh
  • Patent number: 8975370
    Abstract: The present invention relates to a chimeric inhibitor protein of a protease comprising an inhibiting polypeptidic sequence and at least one polypeptidic sequence of a substrate-enzyme interaction site specific for a protease. Other objects of the invention are to provide a purified and isolated DNA sequence encoding the chimeric inhibitor protein of a protease, an expression vector characterized in that it comprises said purified and isolated DNA sequence, a eukaryotic or prokaryotic host cell transformed with this expression vector and a method of producing a chimeric inhibitor protein.
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: March 10, 2015
    Assignee: Universite de Lausanne
    Inventors: David Deperthes, Sylvain Cloutier
  • Patent number: 8975032
    Abstract: The object of the present invention is to provide: a test kit for an antibody titer or an antibody against a periodontal disease-causing bacterium in a blood sample, which enables the testing on a periodontal disease in patients having a wide scope of immunotypes with high accuracy and can be treated by an automated device at a high speed; a periodontal disease-causing bacterium antigen protein which can be suitably used in the kit; a method for testing an antibody titer or the presence of an antibody in a blood sample using the kit; and a kit for typing strains of Porphyromonas gingivalis.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: March 10, 2015
    Assignee: Sunstar Inc.
    Inventor: Mikio Nozoe
  • Patent number: 8969288
    Abstract: Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: March 3, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Binbin Kou
  • Patent number: 8969017
    Abstract: The present invention provides methods for differentiating a pediatric subject with pediatric septic shock from a healthy pediatric subject or one having sudden inflammatory response syndrome (SIRS). Also provided is a method of predicting pediatric septic shock mortality in a pediatric septic shock patient.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: March 3, 2015
    Assignees: UTI Limited Partnership, Children's Hospital Medical Center
    Inventors: Beata Mickiewicz, Hans J. Vogel, Hector R. Wong, Brent W. Winston
  • Patent number: 8969289
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: March 3, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • Patent number: 8969016
    Abstract: A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. Preferably, the construct is selected from the group consisting of CFP-(SGLRSRA)-SNAP-25-(SNS)-YFP, and CFP-(SGLRSRA)-synaptobrevin-(SNS)-YFP. In preferred embodiments, the linker peptide is a substrate of a botulinum neurotoxin selected from the group consisting of synaptobrevin (VAMP), syntaxin and SNAP-25, or a fragment thereof that can be recognized and cleaved by the botulinum neurotoxin. Advantageously, the spacer increases the electronic coupling between the donor label and the acceptor label relative to a corresponding construct without the spacer.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: March 3, 2015
    Assignee: Biomadison, Inc.
    Inventors: Robert D. Fish, Min Dong
  • Patent number: 8969524
    Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: March 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
  • Patent number: 8969018
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: March 3, 2015
    Assignee: Alere San Diego, Inc.
    Inventors: Gunars Valkirs, Paul H. McPherson
  • Patent number: 8968750
    Abstract: The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for use as malaria vaccines. It further relates to compositions comprising said peptides and to the use of such compositions as malaria vaccines.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: March 3, 2015
    Assignee: Ruprecht-Karls-Universität Heidelberg
    Inventors: Ann-Kristin Mueller, Eva Morath
  • Patent number: 8969298
    Abstract: An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: March 3, 2015
    Assignees: Daiichi Sankyo Co., Ltd.
    Inventors: Masaru Matsumoto, Masako Matsumoto, Takeshi Hanada, Naomi Wakabayashi